Page 19 - Confidence Interval News Today : Breaking News, Live Updates & Top Stories | Vimarsana

1. In this randomized-controlled trial, two 12-day courses of teplizumab improved C-peptide levels compared to placebo at week 78 in patients with stage three type 1 diabetes. 2. No significant differences were observed between the teplizumab and placebo groups with respect to secondary clinical outcomes, including clinically relevant hypoglycemic events. Evidence Rating Level: 1 (Excellent)

Welcome to the 2 Minute Medicine Podcast, summarizing the latest medical studies, curated and written by practicing physicians. On this podcast, twice a month, we cover the latest in healthcare news and research evidence. Our episode is live! Episode Description We begin this episode by discussing our article of the week from Annals of Internal

The FDA has approved eplontersen (Wainua) for treating polyneuropathy in adult patients with hereditary transthyretin-mediated amyloidosis, making it the only medication approved for self-administration via auto-injector pen for this condition.

1. In this randomized controlled trial, insulin icodec demonstrated superior HbA1c reduction as compared to once-daily basal insulin analogs in insulin-naïve type two diabetes (T2D). 2. Insulin icodec showed improved treatment satisfaction and compliance as compared to once-daily basal insulin analogs in insulin naïve T2D. Evidence Rating Level: 1 (Excellent) Study Rundown: Two prior phase three randomized

– PADCEV plus pembrolizumab approved based on groundbreaking EV-302 trial –– Confirmatory trial found PADCEV plus pembrolizumab nearly doubled median overall survival compared to standard of care platinum-based chemotherapy –NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE:450...